Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
Introduction: Treatment of hidradenitis suppurativa (HS) remains a challenge in clinical practice for dermatologists. Although the efficacy and safety of secukinumab (SEC) in the treatment of HS has been demonstrated in phase III studies, real-world data is limited. Objectives: We conducted a ret...
Saved in:
Main Authors: | Ece Erbağcı, Özge Sevil Karstarlı Bakay, Fatma Aslı Hapa |
---|---|
Format: | Article |
Language: | English |
Published: |
Mattioli1885
2025-01-01
|
Series: | Dermatology Practical & Conceptual |
Subjects: | |
Online Access: | https://dpcj.org/index.php/dpc/article/view/4915 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hidradenitis Suppurativa-Like Tuberculosis: A Warning for Dermatologists
by: Jose Paulo Ribeiro Junior, et al.
Published: (2025-01-01) -
Immediate versus Delayed Wound Closure in Hidradenitis Suppurativa Surgery: A Comparative Outcomes Study
by: Ehud Fliss, et al. -
Acquired Lymphangioma Circumscriptum of Vulva in a Patient With Hidradenitis Suppurativa: A Rare Case at a Rare Site
by: Ranju Pokharel, et al.
Published: (2025-01-01) -
Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01) -
Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
by: Travis C. Frantz, MD, et al.
Published: (2025-03-01)